Do Nasal Sprays Negate SARS-CoV-2
Xlear Inc. today announced it had supplemented the numerous scientific studies it has already provided the U.S. Department of Justice(DOJ) and the Federal Trade Commission (FTC) in the government's lawsuit against Xlear.
The DOJ-FTC sued Xlear alleging prior statements about nasal hygiene and COVID-19 lacked adequate substantiation.
As of February 27, 2023, Xlear stated in a press release it provided additional studies showing that simple nasal sprays are effective in helping reduce the transmission of (the SARS-CoV-2 virus) COVID-19 and reduce the severity of illness when used by individuals already infected with the virus.
One of the studies Xlear provided to DOJ is a peer-reviewed, double-blind, placebo-controlled, randomized clinical trial (RCT) involving 556 "high-risk healthcare professionals," finding that a nasal spray containing water, saline, and xylitol significantly reduced the transmission of COVID-19 and the severity of cases among those infected.
Specifically, the study finds: "[The spray] significantly reduced SARS-CoV-2 infection compared to placebo [36 cases (13.1%) Vs. 97 cases (34.5%); OR 0.29 (95% CI; 0.18–0.45), p < 0.0001].
Fewer clinical symptoms were also seen in the test group [57 cases (17.6%) vs. 112 cases (34.6%); OR 0.40, (95% CI; 0.27–0.59), p < 0.0001].
No harmful effects were associated with taking the [nasal spray] . . . This represents a 62% relative risk reduction in infection rate."
"[T]he spray was administered up to three times per day with . . . 6–8 [hour] between doses."
The study concludes: "[The nasal spray] has been shown to significantly reduce SARS-CoV-2 infections in healthcare workers, with 62% fewer infections when compared to placebo."
The company says, 'This product is not intended to diagnose, treat, cure, or prevent any disease.'